Vion Pharmaceuticals Reports Status of Clinical Trials and Activities At Annual Stockholders` Meeting July 26
... different types of cancer. * TAPET(R): TAPET is a genetically modified Salmonella vector that was shown in preclinical studies to accumulate preferentially in tumors and is therefore a promising vector for delivery of continuous and high concentrations of anticancer agents......VNP40101M also showed broad anti-cancer activity in preclinical studies and was also able to cross the blood-brain barrier,...
Jul 26 7:40 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010726/nyth039.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines